FBXW7 Mutation

CI-VAR-00002661Explore in graph →CIViC 281

Curated evidence

Evidence by cancer (2 items)

Grouped by cancer context first, then therapy. The same variant can be sensitizing in one cancer and irrelevant in another — contexts are never merged. 50 items per page; a cancer group may continue on the next page.

civicCuratedShowing 1–2 of 2 evidence items across 2 cancer contexts on this page · levels, directions and significance as curated at the source; each row links to its CIViC record.

Molecular profile	Therapy	Type	Level	Direction · significance	Rating (1–5)	Status	Evidence	Source
Malignant Colorectal Neoplasm1
FBXW7 Mutation	Cetuximab + PanitumumabSubstitutes	Predictive	B	Supports Resistance	2	accepted	EID718 65 patients were retrospectively analyzed for mutational profiles predictive of response to EGFR-inhibitors (cetuximab or panitumumab). FBXW7 mutation was found to be more prevalent in non-responders … (full text at CIViC) PMID 26508446 · Lupini et al., 2015 · Open in CIViC	civic
Malignant Neoplasm1
FBXW7 Mutation	MTOR Inhibitor	Predictive	B	Supports Sensitivity Response	2	accepted	EID1631 418 patients with advanced cancer were screened for FBXW7 mutations using a multiplex gene panel. 17 FBXW7 mutations were detected (isolated mutation in 2 patients). Ten patients were treated with an …

ClinVar

Clinical significance (0)

ClinVar interpretations are shown as structured records — significance, review status, star rating, conditions — never flattened into one word.

Data not yet available

No ClinVar interpretation attached to this variant.